Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases, lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet. 2014;383:1899-911. doi:10.1016/S0140-6736(14)60685-1..
DOI: 10.1016/S0140-6736(14)60685-1

Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-anayses, and meta-regression analyses of randomized trials. J Hypertens. 2014;32:2285-95. doi:10.1097/HJH.0000000000000378..
DOI: 10.1097/HJH.0000000000000378

Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower0than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet. 2003;361:1149-58. doi:10.2165/00003495-200464002-00005..
DOI: 10.2165/00003495-200464002-00005

Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021-104. doi:10.1093/eurheartj/ehy339..
DOI: 10.1093/eurheartj/ehy339

Кобалава Ж.Д., Конради А.О., Недогода С.В. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786. doi:10.15829/1560-4071-2020-3-3786..
DOI: 10.15829/1560-4071-2020-3-3786

Loyola Correa T, Oliveira I. Association between serum urate and inflammatory markers in young adults: cross-sectional findings from a birth cohort. Annals of the Rheumatic Diseases. 2021;80:1004.2-1004.10. doi:10.1136/annrheumdis-2021-eular.3790..
DOI: 10.1136/annrheumdis-2021-eular.3790

Katsiki N, Papanas N, Fonseca VA, et al. Uric acid and diabetes: Is there a link. Curr Pharm Des. 2013;19(27):4930-7. doi:10.2174/1381612811319270016..
DOI: 10.2174/1381612811319270016

Maloberti A, Giannattasio C, Bombelli M, et al.; Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension (SIIA). Hyperuricemia and Risk of Cardiovascular Outcomes: The Experience of the URRAH (Uric Acid Right for Heart Health) Project. High Blood Press Cardiovasc Prev. 2020;27(2):121-8. doi:10.1007/s40292-020-00368-z..
DOI: 10.1007/s40292-020-00368-z

Georgiopoulos G, Tsioufis C, Kalos T et al. Serum Uric Acid is Independently Associated with Diastolic Dysfunction in Apparently Healthy Subjects with Essential Hypertension. Curr Vasc Pharmacol. 2019;17(1):99-106. doi:10.2174/1570161116666171226124959..
DOI: 10.2174/1570161116666171226124959

Tu CM, Tseng GS, Liu CW. Serum Uric Acid may be Associated with Left Ventricular Diastolic Dysfunction in Military Individuals. Mil Med. 2020:usaa413. doi:10.1093/milmed/usaa413. Epub ahead of print..
DOI: 10.1093/milmed/usaa413. Epub ahead of print

Podpalova O, Mrochek A. High level of serum uric acid is a predictor of development of carotid artery plaques in new cases of hypertension in urban randomized population regardless of metabolic syndrome. Journal of Hypertension. 2019;37:e281. doi:10.1097/01.hjh.0000573588.73767.d8..
DOI: 10.1097/01.hjh.0000573588.73767.d8

Шальнова С.А., Деев А.Д., Артамонова Г.В. и др. Гиперурикемия и ее корреляты в российской популяции (результаты эпидемиологического исследования ЭССЕ-РФ). Рациональная фармакотерапия в кардиологии. 2014;10(2):153-9. doi:10.20996/1819-6446-2014-10-2-153-159..
DOI: 10.20996/1819-6446-2014-10-2-153-159

Wu AH, Gladden JD, Ahmed M, et al. Relation of serum uric acid to cardiovascular disease. Int J Cardiol. 2016;213:4-7. doi:10.1016/j.ijcard.2015.08.110..
DOI: 10.1016/j.ijcard.2015.08.110

Hou L, Zhang M, Han W, et al. Influence of Salt Intake on Association of Blood Uric Acid with Hypertension and Related Cardiovascular Risk. PLoS One. 2016;11(4):e0150451. doi:10.1371/journal.pone.0150451..
DOI: 10.1371/journal.pone.0150451

Leiba A, Vinker S, Dinour D, et al. Uric acid levels within the normal range predict increased risk of hypertension: a cohort study. J Am Soc Hypertens. 2015;9(8):600-9. doi:10.1016/j.jash.2015.05.010..
DOI: 10.1016/j.jash.2015.05.010

Ando K, Takahashi H, Watanabe T, et al. Impact of Serum Uric Acid Levels on Coronary Plaque Stability Evaluated Using Integrated Backscatter Intravascular Ultrasound in Patients with Coronary Artery Disease. J Atheroscler Thromb. 2016;23(8):932-9. doi:10.5551/jat.33951..
DOI: 10.5551/jat.33951

Dai XM, Wei L, Ma LL, et al. Serum uric acid and its relationship with cardiovascular risk profile in Chinese patients with early-onset coronary artery disease. Clin Rheumatol. 2015;34(9):1605-11. doi:10.1007/s10067-015-2878-1..
DOI: 10.1007/s10067-015-2878-1

Кобалава Ж.Д., Котовская Ю.В., Толкачева В.В., Мильто А.С. Мочевая кислота — ключевой компонент "кардиоренометаболического континуума". Кардиоваскулярная терапия и профилактика. 2008;7(4):95-100. EDN ILJVLN.

Grayson PC, Kim SY, LaValley M, et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011;63(1):102-10. doi:10.1002//acr.20344..
DOI: 10.1002//acr.20344

Kuwabara M, Borghi C, Cicero AFG, et al. Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: A five-year cohort study in Japan. Int J Cardiol. 2018;261:183-8. doi:10.1016/j.ijcard.2018.03.045..
DOI: 10.1016/j.ijcard.2018.03.045

Kuwabara M, Niwa K, Hisatome I, et al. Asymptomatic Hyperuricemia Without Comorbidities Predicts Cardiometabolic Diseases: Five-Year Japanese Cohort Study. Hypertension. 2017;69(6):1036-44. doi:10.1161/HYPERTENSIONAHA.116.08998..
DOI: 10.1161/HYPERTENSIONAHA.116.08998

Cuspidi C, Facchetti R, Bombelli M, et al. Uric Acid and New Onset Left Ventricular Hypertrophy: Findings From the PAMELA Population. Am J Hypertens. 2017;30(3):279-85. doi:10.1093/ajh/hpw159..
DOI: 10.1093/ajh/hpw159

Savage PJ, Pressel SL, Curb JD, et al. Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med 1998;158:741-51. doi:10.1001/archinte.158.7.741..
DOI: 10.1001/archinte.158.7.741

Peterzan MA, Hardy R, Chaturvedi N, et al. Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension. 2012;59:1104-9. doi:10.1161/HYPERTENSIONAHA.111.190637..
DOI: 10.1161/HYPERTENSIONAHA.111.190637

Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension: data from three randomised double-blind studies. Drug Saf. 2001;24:1155- 65. doi:10.2165/00002018-200124150-00006..
DOI: 10.2165/00002018-200124150-00006

Ambrosioni E, Safar M, Degaute JP, et al. Low-dose antihypertensive therapy with 1.5 mg sustainedrelease indapamide: results of randomised double-blind controlled studies. European study group. J Hypertens. 1998;16:1677-84. doi:10.1097/00004872-199816110-00015..
DOI: 10.1097/00004872-199816110-00015

Puig JG, Marre M, Kokot F, et al. Efficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes. Am J Hypertens. 2007;20(1):90-7. doi:10.1016/j.amjhyper.2006.05.018..
DOI: 10.1016/j.amjhyper.2006.05.018

Semenkin AA, Zhivilova LA, Golevtsova Z, et al. Comparative assessment of hypotensive, metabolic, and endothelial effects of indapamide-retard and hydrochlorothiazide in patients with essential hypertension. Kardiologiia. 2006;46:35-9. EDN XWMGNV.

Musini VM, Nazer M, Bassett K, et al. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev. 2014;5:CD003824. doi:10.1002/14651858.CD003824.pub2..
DOI: 10.1002/14651858.CD003824.pub2

Мазуров А. Л., Трухан Д.И. Сравнительная характеристика индапамида и гидрохлоротиазида. Современные наукоемкие технологии. 2010;2:100-1. EDN KZKVYJ.

Farsang С, Dézsi С, Brzozowska-Villatte R, et al. Beneficial Effects of a Perindopril/ Indapamide Single-Pill Combination in Hypertensive Patients with Diabetes and/or Obesity or Metabolic Syndrome: A Post Hoc Pooled Analysis of Four Observational Studies. Adv Ther. 2021;38:1776-90.

Кобалава Ж.Д., Толкачева В.В., Багманова Н.Х. и др. Эффективность и переносимость Арифама у пациентов с артериальной гипертонией старше 55 лет: основные результаты наблюдательной программы АРБАЛЕТ. Российский кардиологический журнал. 2018;23(12):64-74. doi:10.15829/1560-4071-2018-12-64-74..
DOI: 10.15829/1560-4071-2018-12-64-74

Tóth K, PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/ indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs. 2014;14(2):137-45. doi:10.1007/s40256-014-0067-2..
DOI: 10.1007/s40256-014-0067-2

Кобалава Ж.Д., Троицкая Е.А., Толкачева В.В. Комбинированная терапия артериальной гипертонии с использованием трехкомпонентной фиксированной комбинации амлодипина, индапамида и периндоприла аргинина в клинической практике: организация и основные результаты программы ДОКАЗАТЕЛЬСТВО. Кардиология. 2018;58(9):21-30. doi:10.18087/cardio.2018.9.10170..
DOI: 10.18087/cardio.2018.9.10170